BCAX Share Price Performance
US$21.98
11.83 (116.55%)
27.9% undervalued intrinsic discount
US$30.50
Fair Value
Price US$21.98
AnalystConsensusTarget US$30.50
Fair ValueUS$30.50
Share Pricen/a
Bicara Therapeutics Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
BCAX Community Narratives
AN
Fair Value US$30.5 27.9% undervalued intrinsic discount
Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer
Catalysts About Bicara Therapeutics Bicara Therapeutics is a clinical stage biotech company focused on bifunctional antibodies for targeted tumor modulation, led by its FICERA program in HPV negative head and neck cancer. What are the underlying business or industry changes driving this perspective?Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$30.5
27.9% undervalued intrinsic discount
Fair Value
Profit Margin
14.76%
Future PE
479.27x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Pivotal Head And Neck Cancer Trial Will Reshape Prospects For This Bifunctional Antibody Developer
Fair Value: US$30.5 27.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Bicara Therapeutics Inc. Key Details
About BCAX
- Founded
- 2018
- Employees
- 103
- CEO
- WebsiteView website
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
